Steven P. Rowe, MD, PhD, presented “Radiopharmaceuticals in Advanced Prostate Cancer” during the 2024 Frontiers in Oncologic Prostate Care and Ablative Local Therapy symposium on October 17, 2024, in San Diego, California.
>
How to cite: Rowe, Steven P. “Radiopharmaceuticals in Advanced Prostate Cancer.” October, 2024. Accessed Jan 2025. https://grandroundsinurology.com/radiopharmaceuticals-in-advanced-prostate-cancer/
Radiopharmaceuticals in Advanced Prostate Cancer – Summary
Steven P. Rowe, MD, PhD, delves into the transformative potential and challenges of radioligand therapy in managing advanced prostate cancer. In this 21-minute presentation, Dr. Rowe emphasizes the excitement surrounding the efficacy and tolerability of agents like lutetium PSMA-617, contrasting them with harsher cytotoxic treatments. A nuanced discussion addresses pitfalls in PSMA PET imaging, highlighting false positives and underscoring the necessity of careful interpretation.
Toxicity management and manageable side effects are discussed. Innovations in imaging biomarkers and longitudinal PSMA PET imaging are positioned as tools to refine response assessment and personalize therapy.
Given differences in training and systemic constraints, challenges in translating European advancements to US practice are acknowledged. Further, Dr. Rowe critiques limitations in AI and radiomics applications for PET scans, highlighting the inability to characterize findings accurately. Ultimately, Dr. Rowe advocates integrating PSMA PET into clinical trials and enhancing therapy stratification to maximize patient benefit.
Frontiers in Oncologic Prostate Care and Ablative Local Therapy (FOCAL) is an outstanding program on prostate imaging, transperineal interventions, and ablative treatments for prostate cancer and benign prostatic hyperplasia. Bringing together community-based, academic, and industry partners, FOCAL offers lectures by world-renowned faculty and hands-on training workshops on in-office transperineal interventions, fusion-guided prostate ablation and state-of-the-art BPH management with novel technologies.
ABOUT THE AUTHOR
Steven P. Rowe, MD, PhD, is an Associate Professor of Radiology and Radiological Science at Johns Hopkins University in Baltimore, Maryland. He clinically practices both diagnostic radiology and nuclear medicine, and his research work focuses on applications of novel molecular imaging agents for positron emission tomography (PET) and single-photon emission computed tomography (SPECT). He is particularly interested in the use of prostate-specific membrane antigen (PSMA)-targeted PET agents in prostate cancer and renal cell carcinoma, as well as the clinical utilization of 99mTc-sestamibi SPECT for non-invasive characterization of renal masses. He and his colleagues recently developed and validated a structured reporting system for delineating and codifying findings on PSMA PET known as PSMA Reporting and Data System (PSMA-RADS).
